
RESEARCH SQUARE – A NEW MODEL OF PUBLISHING

Damian Pattinson
FuturePub London
March 2019




Preprints, yay!





Data from Prepubmed.org

Preprints, meh






ng

%

Publications with preprints — the Ebola and Zika outbreaks





PLOS Authors Say "Yes" to Preprints

Posted December 6, 2018 by Madison Crystal in Innovation, Open Access, Open Science, Progress Update, Science communication



We've surpassed 1,300 preprint posts to bioRxiv!

This is an incredible milestone for us and for all of our authors who chose to opt-in to our preprint service since we announced our partnership with Cold Spring Harbor Laboratory's bioRxiv six months ago. We wanted to bring an easy preprint-posting option directly to the submission process for our authors and are thoroughly excited with the results we've seen so far.

The road to preprints

As we began this journey, about 4% of our authors reported that they had posted their submission to a preprint server. While this base remains consistent, our preprint-posting service has built upon it to offer authors more choices. In the past six months we've seen an additional 14% opt-in to have PLOS post a preprint on their behalf, indicating that 18% of our authors want to use preprints to share their research.



Recent Posts



We Couldn't Do It without YOU



Celebrate Open Data Day with Us! March 1, 2019



'How do we define success?' -...
February 21, 2019

PLOS Channels peer review week

preprints collaboration

early career researcher Interview discovery figshare science publishing community diversity thank you science communication reproducibility advocacy open source Open

bioRxiv editors Zika data management

Open Access transparency recognition featured peer review

leadership ehola PLOS

Research Article

Pattern and Presentation of Vitreo-Retinal Diseases: Lessons from a Tertiary Eye Care Centre in Nepal

Bhim Bahadur Rai Mohan K. Shresthra Raba Thapa Rohan W. Essex Govinda Paudyal Ted Maddess



Article

Hypothesis annotations

Version 1 ▼

Submitted 12 December 2018 • DOI: https://doi.org/10.21203/rs.2.82/v1

This is the most recent version of this article. Please note that this article has not completed peer-review.

ABSTRACT

Background: We examined patients presenting in a tertiary eye hospital in Nepal, focussing on information for screening and management programs for vitreo-retinal disease (VR).

Methods: We reviewed all patients presenting for the first time to the VR-clinic over one year. We quantified patient demography, symptoms and duration, associated systemic diseases, ophthalmological examinations, diagnostic investigations and final diagnoses.

Results: Of the 1905 cases 1148 were males (60.3%). The 25th-percentile of ages was 29 and 38 years for males and females respectively, indicating females presented later (p<0.0001). Hypertension was the commonest systemic disease (40.8%), followed by diabetes (32.5%). Macular degeneration (AMD) and diabetic retinopathy (DR) affected 447 eyes (11.8%), and 416 eyes (10.9%) respectively. Male and female AMD and DR patients did not differ in age or disease duration, which for DR was not correlated with severity. Asymmetry of disease severity between AMD and DR eyes was largest in patients with one normal eye. Presenting acuity was highly asymmetric between eyes (p<0.0001) with people more often reporting when their dominant eyes had acuity of 6/18 or worse.

Conclusions: When left to self-report patients tended to not notice visual impairment in their non-dominant eye until

Article-level metrics

Comments: 4 PDF Downloads: 0 HTML Views: 243

■ Wersion 1
Submitted 12 Dec, 2018

Community Comments

Subject Areas

Internal Medicine Specialties

Keywords

AMD, diabetic retinopathy, retinal diseases, laterality, ocular dominance, sex differences

More from

Macular Vessel Density, Perfusion Density, Foveal

BMC *In Review*



In Review

See your manuscript's review progress with our first-of-its-kind In Review service

Our commitment to research in progress and openness inspires us to think about how to help our authors in new ways. So, together with our partners at Research Square, we've added a new option for you when you submit to BMC Neurology, Trials. This new option, called In Review, gives you insight over your manuscript's editorial progress; even while it's out for review.




With In Review you can:

- Track the status of your manuscript, including when reviews have been received
- Share your work with funders and others in a citeable way while it is under review, and
 engage the wider community in discussion to help make your article even better
 including through the Hypothes.is open annotation tool
- Demonstrate the integrity of your work with a transparent editorial checklist



Author opt-in



By opting in to the free *In Review* platform, your paper will be posted publicly as a preprint so you can **showcase your work to funders** and others in a citable way.

Want to know the status of your paper? In Review also gives you access to the Peer Review Timeline, which provides on-demand access to the status of your manuscript including number of reviewers invited and number of reports received.

Worried about sharing your work early? Don't! You'll receive a DOI which timestamps your paper so you can claim your work as soon as possible. You can read more about *In Review* here. If you choose to opt in, all versions of your manuscript will be posted as and when they are available.

By opting in to *In Review*, you confirm to us that your submission does not violate other parties' copyright or other proprietary rights. You also confirm that you accept our Terms of Use and licencing terms. Please let us know if you would like to participate in *In Review* by selecting an option below:

Answer Required:

Please select a response

Yes, I would like to opt in and direct Research Square to upload this material to the In Review platform on my behalf.

No, I do not wish to opt in to the In Review service.

Please select a response.


Instruction for Au

ce

a users: Please click on the word "Register" in the navigation has at the top of the nage and enter the requested information. Upon successful register



Public Article page



Review history – updated in real time whenever there is a status change




SPRINGER NATURE

https://www.researchsquare.com/company/publishers/pre-publication-platform

Full Peer Review History:

Updated as soon as a review

Author view



Peer Review Timeline

Submitted 23 Aug, 2018

Published

On 20 Aug, 2018

Community comments: 7

☑ Editorial decision: Accept

■ - Version 3

■ - Version 2

Research Square

ABSTRACT

Background: Nucleophosmin is a non-ribosomal nucleolar phosphoprotein that is found primarily in the nucleolus region of cell nucleus, plays multiple important roles in tumor processes. Accumulated previous studies have

reported a potential value of NPM acted as a biomarker for prognosis in various solid tumors, but the results were

more inconsistency. We performed this meta-analysis to precisely evaluate the prognostic significance of NPM in

solid tumors. Methods: Clinical data were collected from a comprehensive literature search in PubMed, Web of Science, Embase, and China National Knowledge Infrastructure databases (up to October, 2017). A total of 11 studied

with 997 patients were used to assess the association of NPM expression and patients' overall survival (OS). The

incorporated into the review package sent to editor

Opt-in rate

Journal	Submissions to "In Review"	Total Submissions (since 18 Oct)	Opt-in rate (%)
Trials	353	852	41%
BMC Neurology	334	585	57%
BMC Anaesthesiology	281	462	61%
BMC Ophthalmology	342	603	57%
TOTAL	1310	2502	52%




Next steps

- Adding more journals
- Hosting Nature Protocol Exchange
- Launching direct submission pathway
- Adding editorial services
- Building community review functionality



Community review modules







Journals Users Dashboard

6 Comments



Eli Pradhan • 17 December 2018

The comments are below

Abstract: In the background part, it is written screening. However, I feel Screening part should be omitted and use appropriate word (Is it screening as all pts are already seen by General Ophthalmologist in the general clinic and referred to Special clinic?)

Methodology: Please mention what type of study is this? Cross sectional? Retrospective? Prospective. Type of study is lacking.

IRC no 10/2018; Is it back dated?

Results show 41.2% from kathmandu, probably it is better to mention the reason for it.

Conclusion: Is the data of education status pf the patients taken? Can we comment on education if there is no data taken?

Thank you for providing me the opportunity

Dr Eli Pradhan, MD, MRSCEd, Consultant Medical Retina

Reply to comment • Flag for moderation



Bhim B. Rai • 18 December 2018

Dear Dr. Pradhan,

Thank you so much for your valuable input. I am replying to your comments point wise:

- 1. Abstract: We have mentioned screening because not all patients were referred by the general ophthalmologists, and the retinal specialists would surely screened them for correct diangoses.
- 2. Methodology: we have mentioned retrospective study in the method section, sub-section setting. I agree it is not obvious and we needed to create separate paragraph. We are waiting for the reviewers' comments and surely consider your feedback in improving our maniscript.
- 3. This retrograde study is the analysis of the existing data. So the clearance was given then for data collection and again renewed vide letter number TIO-IRC Ref: 10/2018.
- 4. Majority (54.5%) of patients were from Nepal outsied Kathmandu and only 41.2% were from within Kathmandu. This indicates patients travel to TIO from all over Nepal to access the treatment at TIO reflecting the high quality of patient care an mandgement. [we mentioned this in our draft but had to delete it due to word limit].



Automation in action





Useful links

Commented articles:

 $\underline{https://www.researchsquare.com/article/0895c729-0216-4dfd-9e4a-bdee2f1097d1/v1}$

https://www.researchsquare.com/article/2f956f29-ffe1-46f8-a7ff-f3aeb214c4c2/v1

Homepages:

